share_log

DaVita | 8-K: Current report

DaVita | 8-K: Current report

德维特 | 8-K：重大事件
美股SEC公告 ·  2024/08/06 15:13

Moomoo AI 已提取核心信息

DaVita delivered solid financial performance in Q2 2024, with consolidated revenues reaching $3.19 billion and operating income of $506 million, representing a 15.9% operating margin. Diluted earnings per share was $2.50, while adjusted diluted EPS reached $2.59. The company generated robust operating cash flow of $799 million and free cash flow of $654 million.U.S. dialysis operations showed positive momentum with total treatments of 7.27 million, up 1.1% QoQ. Average patient service revenue per treatment increased to $390.22 from $384.54 in Q1 2024, driven by seasonal improvements in patient insurance deductibles and normal annual rate increases, partially offset by unfavorable payor mix changes.The company continued its capital return program, repurchasing 2.7 million shares at an average price of $140.14 per share. Additionally, DaVita extended the maturity date for $1.64 billion of Term Loan B-1 and maintained strong integrated kidney care growth with 71,300 risk-based patients representing approximately $5.4 billion in annualized medical spend.
DaVita delivered solid financial performance in Q2 2024, with consolidated revenues reaching $3.19 billion and operating income of $506 million, representing a 15.9% operating margin. Diluted earnings per share was $2.50, while adjusted diluted EPS reached $2.59. The company generated robust operating cash flow of $799 million and free cash flow of $654 million.U.S. dialysis operations showed positive momentum with total treatments of 7.27 million, up 1.1% QoQ. Average patient service revenue per treatment increased to $390.22 from $384.54 in Q1 2024, driven by seasonal improvements in patient insurance deductibles and normal annual rate increases, partially offset by unfavorable payor mix changes.The company continued its capital return program, repurchasing 2.7 million shares at an average price of $140.14 per share. Additionally, DaVita extended the maturity date for $1.64 billion of Term Loan B-1 and maintained strong integrated kidney care growth with 71,300 risk-based patients representing approximately $5.4 billion in annualized medical spend.
德维特在2024年第二季度实现了稳健的财务表现，合并营业收入达到31.9亿美金，营业收入为50600万美金，营业利润率为15.9%。摊薄后每股收益为2.50美金，而调整后的摊薄后每股收益达到2.59美金。公司创造了强劲的营业现金流79900万美金和自由现金流65400万美金。美国透析业务显示出积极的势头，总治疗次数达到727万，同比增长1.1%。每次治疗的平均患者服务收入从2024年第一季度的384.54美金增加到390.22美金，受季节性患者保险自付额改善和正常年度涨幅的推动，部分被不利的付款者组成变化所抵消。公司继续其资本回报计划，以平均每股140.14美金的价格回购270万股股票。此外，德维特延长了16.4亿美金的Term Loan b-1的到期日，并维持了强劲的综合肾脏护理增长，71,300名基于风险的患者代表每年约54亿美金的医疗支出。
德维特在2024年第二季度实现了稳健的财务表现，合并营业收入达到31.9亿美金，营业收入为50600万美金，营业利润率为15.9%。摊薄后每股收益为2.50美金，而调整后的摊薄后每股收益达到2.59美金。公司创造了强劲的营业现金流79900万美金和自由现金流65400万美金。美国透析业务显示出积极的势头，总治疗次数达到727万，同比增长1.1%。每次治疗的平均患者服务收入从2024年第一季度的384.54美金增加到390.22美金，受季节性患者保险自付额改善和正常年度涨幅的推动，部分被不利的付款者组成变化所抵消。公司继续其资本回报计划，以平均每股140.14美金的价格回购270万股股票。此外，德维特延长了16.4亿美金的Term Loan b-1的到期日，并维持了强劲的综合肾脏护理增长，71,300名基于风险的患者代表每年约54亿美金的医疗支出。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Kindly MD
    KDLY
    -- 2.890
    IMAC Holdings
    BACK
    -- 0.6400
    The Oncology Institute
    TOI
    -- 0.9611
    COMPASS Pathways
    CMPS
    -- 4.570
    Cryo-Cell International
    CCEL
    -- 7.840
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。